Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash ...

In April 2025, our partner Jazz announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of ...

A recent study marks the first reported instance of generative AI designing synthetic molecules that can successfully control gene expression in healthy mammalian cells. As a proof-of-concept, the ...

The Broadmoor Pikes Peak International Hill Climb (PPIHC) has announced the winner of its poster art contest. PPIHC said the ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Conclave speculation, urinal innovation, “Italian brainrot”... and much more.

Cardiff Oncology has sufficient funds to operate until early 2027 but will face funding challenges by 2026. Learn why CRDF ...

DDW 2025 will take place May 3-6, 2025, in San Diego, CA and online. Digestive Disease Week (DDW) 2025: Abstract Number: Mo1549 Session Type: Poster Session Title: Cholelithiasis and Biliary Tract ...

VectorY Therapeutics (VectorY), a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced that it will have four feat ...